Clinigen Group

Clinigen Group is a global pharmaceutical services and products company dedicated to providing ethical access to medicines for patients. The company was formally established in 2010 through the merger of three healthcare businesses by founder Andrew Leaver, with Peter George appointed as CEO to execute a strategy of combining services and products. It floated on the London stock market in 2012. In April 2022, Clinigen was acquired by Triton Investment Management and taken private.

The company's business model is centered on acquiring and revitalizing niche, hospital-only medicines and providing services across the entire pharmaceutical product lifecycle. It operates through three main service divisions: Clinical Services, Access and Commercialisation, and Lifecycle Services. This structure allows Clinigen to partner with pharmaceutical and biotech companies, as well as healthcare professionals, to manage clinical trial supplies, provide access to unlicensed medicines (also known as managed access, compassionate use, or named patient programs), and commercialize pharmaceutical products globally.

Clinigen serves a global client base that includes 22 of the top 25 pharmaceutical companies and interacts with over 15,000 registered users in more than 100 countries. The company's revenue is generated through its services to pharma partners and the sale of its portfolio of medicines, which includes products for oncology, infectious diseases, and rare diseases. The company has grown significantly through a series of strategic acquisitions, including Idis (2015), Link Healthcare (2015), Quantum Pharma (2017), and more recently, Ascenian Consulting and Kinesys Consulting in 2024 to bolster its market access and regulatory affairs capabilities.

Keywords: pharmaceutical services, medicine access, clinical trial supply, unlicensed medicines, managed access programs, commercialisation, pharmacovigilance, regulatory affairs, comparator sourcing, product lifecycle management, specialty pharmaceuticals, hospital-only medicines, global distribution, healthcare services, biotech partnerships, drug revitalization, market access consulting, rare diseases, oncology, infectious disease